231 related articles for article (PubMed ID: 1371415)
1. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin.
Brugger W; Bross K; Frisch J; Dern P; Weber B; Mertelsmann R; Kanz L
Blood; 1992 Mar; 79(5):1193-200. PubMed ID: 1371415
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
Brugger W; Birken R; Bertz H; Hecht T; Pressler K; Frisch J; Schulz G; Mertelsmann R; Kanz L
Br J Haematol; 1993 Jul; 84(3):402-7. PubMed ID: 7692928
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin.
Brugger W; Möcklin W; Heimfeld S; Berenson RJ; Mertelsmann R; Kanz L
Blood; 1993 May; 81(10):2579-84. PubMed ID: 7683923
[TBL] [Abstract][Full Text] [Related]
4. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.
Brugger W; Frisch J; Schulz G; Pressler K; Mertelsmann R; Kanz L
J Clin Oncol; 1992 Sep; 10(9):1452-9. PubMed ID: 1517788
[TBL] [Abstract][Full Text] [Related]
5. Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors.
Siena S; Bregni M; Bonsi L; Sklenar I; Bagnara GP; Bonadonna G; Gianni AM
Exp Hematol; 1993 Nov; 21(12):1583-90. PubMed ID: 7691640
[TBL] [Abstract][Full Text] [Related]
6. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
7. Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor.
Dai CH; Krantz SB; Dessypris EN; Means RT; Horn ST; Gilbert HS
Blood; 1992 Aug; 80(4):891-9. PubMed ID: 1498332
[TBL] [Abstract][Full Text] [Related]
8. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane.
Janowska-Wieczorek A; Marquez LA; Nabholtz JM; Cabuhat ML; Montaño J; Chang H; Rozmus J; Russell JA; Edwards DR; Turner AR
Blood; 1999 May; 93(10):3379-90. PubMed ID: 10233890
[TBL] [Abstract][Full Text] [Related]
9. Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
Vogel W; Kunert C; Blumenstengel K; Fricke HJ; Kath R; Sayer HG; Höffken K
J Cancer Res Clin Oncol; 1998; 124(6):341-5. PubMed ID: 9692843
[TBL] [Abstract][Full Text] [Related]
10. Effect of murine mast cell growth factor (c-kit proto-oncogene ligand) on colony formation by human marrow hematopoietic progenitor cells.
Broxmeyer HE; Cooper S; Lu L; Hangoc G; Anderson D; Cosman D; Lyman SD; Williams DE
Blood; 1991 May; 77(10):2142-9. PubMed ID: 1709371
[TBL] [Abstract][Full Text] [Related]
11. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients.
Nowrousian MR; Waschke S; Bojko P; Welt A; Schuett P; Ebeling P; Flasshove M; Moritz T; Schuette J; Seeber S
Ann Oncol; 2003; 14 Suppl 1():i29-36. PubMed ID: 12736228
[TBL] [Abstract][Full Text] [Related]
12. Haematopoietic growth factors and peripheral blood stem cells as supportive agents in dose intensification.
Kanz L; Brugger W; Mertelsmann R
Eur J Cancer; 1993; 29A Suppl 5():S23-6. PubMed ID: 8260263
[TBL] [Abstract][Full Text] [Related]
13. Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy.
Venturini M; Del Mastro L; Melioli G; Balleari E; Garrone O; Pasquetti W; Bason C; Ghio R; Bruzzi P; Rosso R
Cancer; 1994 Oct; 74(8):2300-6. PubMed ID: 7522948
[TBL] [Abstract][Full Text] [Related]
14. Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study.
Ganser A; Lindemann A; Ottmann OG; Seipelt G; Hess U; Geissler G; Kanz L; Frisch J; Schulz G; Herrmann F
Blood; 1992 May; 79(10):2583-91. PubMed ID: 1586711
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human granulocyte-macrophage colony-stimulating factor in septic neutropenic pediatric cancer patients: detection of circulating hematopoietic precursor cells correlates with rapid granulocyte recovery.
Fink FM; Maurer-Dengg K; Fritsch G; Mann G; Zoubek A; Falk M; Gadner H
Med Pediatr Oncol; 1995 Nov; 25(5):365-71. PubMed ID: 7545780
[TBL] [Abstract][Full Text] [Related]
16. Combined use of growth factors to stimulate the proliferation of hematopoietic progenitor cells after autologous bone marrow transplantation for lymphoma patients.
Lemoli RM; Fortuna A; Fogli M; Rosti G; Gherlinzoni F; Visani G; Catani L; Gozzetti A; Tura S
Acta Haematol; 1996; 95(3-4):164-70. PubMed ID: 8677737
[TBL] [Abstract][Full Text] [Related]
17. Priming with recombinant human hematopoietic cytokines before bone marrow harvest expands in vivo and enhances ex vivo recovery of myeloid progenitors in short-term liquid cultures.
Johnsen HE; Jensen L; Gaarsdal E; Hansen PB; Ersbøll J; Hansen NE
Exp Hematol; 1994 Jan; 22(1):80-6. PubMed ID: 7506675
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.
Peters WP; Rosner G; Ross M; Vredenburgh J; Meisenberg B; Gilbert C; Kurtzberg J
Blood; 1993 Apr; 81(7):1709-19. PubMed ID: 7681699
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of granulocyte colony-stimulating factor-induced mobilization of circulating progenitor cells by seven-day pretreatment with interleukin-3.
Geissler K; Peschel C; Niederwieser D; Strobl H; Goldschmitt J; Ohler L; Bettelheim P; Kahls P; Huber C; Lechner K; Höcker P; Kolbe K
Blood; 1996 Apr; 87(7):2732-9. PubMed ID: 8639889
[TBL] [Abstract][Full Text] [Related]
20. Expansion of granulocyte colony-stimulating factor/chemotherapy-mobilized CD34+ hematopoietic progenitors: role of granulocyte-macrophage colony-stimulating factor/erythropoietin hybrid protein (MEN11303) and interleukin-15.
Pierelli L; Scambia G; Bonanno G; Coscarella A; De Santis R; Mele A; Battaglia A; Fattorossi A; Romeo V; Menichella G; Mancuso S; Leone G
Exp Hematol; 1999 Mar; 27(3):416-24. PubMed ID: 10089903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
